CLAIMS

1. A method for isolating or producing antibodies, the method comprising:

    - immunizing a female vertebrate animal by administration of at least one protein or peptide comprising at least one amino acid sequence selected from the group consisting of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 - SEQ ID NO: 41,
    - collecting one or more lactation or ovulation product from the animal after immunization, and
    - isolating or purifying at least one antibody from the products,

    wherein the protein or peptide is, comprises, or is a fragment of, the SARS CoV 2 spike protein.

2. The method according to claim 1, wherein the animal is a ruminant selected from the group consisting of cow, pig, camel, horse, goat and sheep, or a bird selected from an anseriform bird and a chicken.

3. The method according to any one of the aforementioned claims, wherein the ovulation product that is collected from the animal is one or more eggs.

4. The method according to any one of the aforementioned claims, wherein the antibody that is purified from the eggs is IgY.

5. The method according to any one of the aforementioned claims, wherein the lactation product collected from the animal is, whey, milk or colostrum.

6. The method according to any one of the aforementioned claims, wherein the antibody is at least one of IgA, IgG, and IgM.

7. The method according to any one of the aforementioned claims, wherein the protein or peptide comprising at least one amino acid sequence selected from the group consisting

of any one of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 - SEQ ID NO: 41 has a maximum length as set forth in table 1.

8. The method according to any one of the aforementioned claims, wherein

a) at least one single chain protein or peptide is used for immunizing which comprises two or more subsequences each comprising an amino acid sequence selected from the group consisting of any one of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 - SEQ ID NO: 41, and/or

b) at least one homo- or heterodimer, -oligomer or -multimer is used for immunizing which comprises two or more chains each comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 – SEQ ID NO 29.

9. The method according to any one of the aforementioned claims, wherein at least one protein or peptide used for immunizing is conjugated to a second molecule known to be immunogenic in the animal being immunized.

10. The method according to any one of the aforementioned claims, wherein the isolation or purification of the antibody comprises the steps of

a) removal of the bulk of the lipids and lipoproteins from the yolk (“delipidation”), and
b) concentration or purification of the IgY fraction.

11. The method according to any one of the aforementioned claims, wherein for immunization, a dosis of between ≥ 0.02 and ≤ 0.5 mg protein or peptide is injected to the bird.

12. The method according to any one of the aforementioned claims, wherein the isolation or purification of the antibody comprises the steps of

a) optionally, skimming milk or colostrum by removing fat
b) removing casein e.g. by lowering pH to 4.6 by adding an acid, and

c) collecting the liquid phase and concentration or purification of the antibody fraction.

13. The method according to any one of the aforementioned claims, wherein for immunization, a dosis of between ≥ 0.05 and ≤ 2 mg protein or peptide is injected to the mammal.

14. The method according to any one of the aforementioned claims, wherein for immunization, an adjuvant is co-administered with the at least one protein or peptide.

15. The method according to any one of the aforementioned claims, wherein immunization is repeated between one and 10 times.

16. The method according to any one of the aforementioned claims, wherein, in the repeated immunization, the amount of the protein or peptide is reduced to between ≥ 70% and ≤ 10 % of the initial dosis.

17. The method according to any one of the aforementioned claims, wherein immunization is performed by in at least two steps, wherein,

    a) in a first step, the bird or mammal is immunized by administration of at least one single chain protein or peptide which comprises two or more subsequences each comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 - SEQ ID NO: 41, and
    b) in a second step performed after the first step the bird or mammal is immunized by administration of at least one monomer which comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 – SEQ ID NO 29.

18. The method according to any one of the aforementioned claims, wherein at least one of the proteins or peptides used for immunization is produced by at least one of peptide synthesis or recombinant expression,

wherein the recombinant expression is done in at least one of

- a prokaryotic expression system,
- a fungal or yeast based expression system,
- a protozoan expression system,
- an baculovirus/insect expression system, and
- a mammalian expression system.

19. An antibody or a combination of two or more antibodies that binds specifically to a protein or peptide comprising a sequence selected from the group consisting of any one of any one of SEQ ID NO: 1 - SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25 or any one of SEQ ID NO: 26 - SEQ ID NO: 41, wherein the protein or peptide is, comprises or is a fragment of the SARS CoV-2 spike protein.

20. The antibody or antibodies according to claim 19, which

- inhibits binding of SARS-Cov2 to the human ACE2 receptor, and/or
- interferes with the priming of the spike protein by blocking proteolytic cleavage thereof at S1/S2 or S2.

21. The antibody or antibodies according to any one of claims 19 - 20, which has/have a neutralizing titer (NT_{50}) of $\leq 1 \times 10^5$.

22. The antibody or antibodies according to any one of claims 19 - 21, which is/are produced by the method according to any one of claims 1 – 18.

23. A product comprising at least one antibody according to any one of claims 19 - 22, the product being provided as at least one selected from the group consisting of

- Lozenge
- Chewing gum
- Tablet
- Cream or gel
- Gargling solution or mouthwash

- liquid solution for topic application
- aerosol for intraoral, intratracheal or intranasal administration, and/or
- aqueous solution for intravenous, subcutaneous or intramuscular administration,

or

the product being embedded or provided in at least one item selected from the group consisting of:

- Breathing mask
- Filter for fluid media, including gases and liquids, and/or
- Disinfectant gel, liquid, aerosol or spray.

24. Use of the antibody or antibodies according to any one of claims 19 - 22 or the product according to claim 23 in the manufacture of a medicament for the treatment of a patient that suffers from or diagnosed for SARS Cov-2 infection, or for the prevention of such condition.

25. The antibody or antibodies, product or use according to any one of the aforementioned claims, the antibody or antibodies being co-administered with, or the product further comprising, at least one of

- a protease inhibitor, preferably an inhibitor of TMPRSS2 or an inhibitor of the CoV-2 C30 endopeptidase (also called Mpro or 3CLpro)
- a nucleoside or nucleotide analogue, preferably which is accepted by viral RNA-dependent RNA polymerase
- an IL-6 antagonist,
- a soluble angiotensin-converting enzyme 2, and/or
- a peptide that comprises a sequence that is homologous to the S1/S2 sequence of the SarsCov2 spike protein,

wherein co-administration can be carried out concomitantly or consecutively.